HCP Plastene (526717)
TurnaroundScore breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹179.3 |
| Market Cap | ₹191.59 Cr |
| P/E Ratio | 9.55 |
| ROCE | 13.23% |
| ROE | 28.36% |
| Dividend Yield | 0.56% |
| Profit Growth | 368% |
| Debt/Equity | — |
| Sales Growth | 1.59% |
| 52-Week Range | ₹140.1 — ₹284.45 |
| Sector | Industrial Products |
| Book Value | ₹39.71 |
Strengths
- Trailing P/E of 9.55 and market cap of ₹192 Cr against ~₹20 Cr trailing profit offer a cheap-looking entry if earnings are sustainable.
- Latest quarter net margin improved to 6.6% (₹8 Cr profit on ₹121 Cr sales), showing better cost or pricing discipline.
- ROE of 28.36% is strong, and Piotroski F-Score of 7/9 indicates healthy fundamentals.
- Price at ₹179 is well below the 52-week high of ₹284, adding potential margin of safety if the turnaround persists.
Concerns
- Revenue growth of just 1.59% does not support 368% profit growth; earnings quality is questionable.
- P/B of 4.52 means paying 4.5 times book; high ROE may be leverage-driven, and debt/equity is not disclosed.
- Latest quarter annualized profit (~₹32 Cr) is far above the trailing implied profit (~₹20 Cr), showing lumpy or inconsistent earnings.
- Dividend yield of only 0.56% gives little income support while waiting.
AI Analysis
Let me start with what the numbers actually say. HCP Plastene, a packaging business, has grown sales by only 1.59%, yet reported a 368% jump in profit. As Graham would ask: is this a business getting better, or earnings recovering from a low base? In a competitive industry like packaging, I see no durable moat in these figures. The shares trade at a P/E of 9.55 and a price-to-book of 4.52, meaning I pay ₹179 for book value of ₹39.71. A 28.36% ROE sounds attractive, but the 13.23% ROCE tells me the return on capital is far more modest. Without a debt-to-equity figure, I cannot confidently judge how much leverage is inflating that ROE. The latest quarter shows sales of ₹121 Cr and profit of ₹8 Cr, which is a 6.6% margin. If annualized, that would suggest ₹32 Cr of profit, yet the trailing P/E implies about ₹20 Cr. That inconsistency warns me that earnings are not stable. The 0.56% dividend yield means I am not being paid to wait. The Piotroski score of 7/9 shows some financial strength, but a score is no substitute for a predictable competitive position. The PEG of 0.03 is a trap: profit growth cannot be 368% every year when revenue barely moves. The share price has fallen from ₹284 to ₹179, so the market has already cooled. This is not a compounder yet. It smells more like a turnaround, where one or two good quarters get extrapolated. I would need several quarters of rising sales and sustained margins before calling it a bargain. For now, I watch, I do not chase.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer